Endocrinology News

WASHINGTON — An algorithm that uses electronic health record parameters identified glycemic evidence of new-onset diabetes in real time, which could lead to earlier detection of pancreatic ductal adenocarcinoma, according to researchers.

WASHINGTON — Parental obesity was associated with a nearly threefold increased risk for metabolic dysfunction-associated steatotic liver disease among offspring in early adulthood, according to data presented at Digestive Disease Week.

Adults in France who consumed more food additive emulsifiers had increased risk for type 2 diabetes, according to a study published in The Lancet Diabetes & Endocrinology.

WASHINGTON — Glucagon-like peptide-1 receptor agonists were associated with lower risk for progression to cirrhosis and hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease and type 2 diabetes.

WASHINGTON — Patients with obesity and metabolic dysfunction-associated fatty liver disease taking glucagon-like peptide-1 receptor agonists had lower risk for all-cause mortality and major cardiovascular events, according to a presenter.

SAN FRANCISCO — An updated evidence-based guideline for the assessment and management of polycystic ovary syndrome includes new recommendations for a timelier diagnosis and evidence that firmly supports PCOS is a risk factor for CVD.

Patients with both diabetes and CAD appeared at significantly greater risk for dementia, especially vascular dementia, according to study findings published in European Journal of Preventive Cardiology.

The disease of obesity often brings cardiometabolic consequences, including hypertension, which remains the most potent and predictive risk factor for cardiovascular disease.

Today, we are closer than ever to achieving the weight loss seen with bariatric surgery, and we are starting to see emerging evidence of cardiovascular risk reduction, type 2 diabetes remission, improvement in heart failure with preserved ejection fraction (HFpEF) and more. This “new” class of medications has been around for more than 18 years. We know the safety profiles; they are manageable.

Last month, the Obesity Medicine Association held its annual conference, where clinicians across the country came together to discuss the latest developments in obesity care.